However, the later published evidence that the two breast cancer CSC populations (i.e., ALDH+ and CD24−/CD44+) investigated reside in different areas of primary breast tumors and can transition from one phenotype to the other (19) might affect the reliability of CSC counts in this patient population. This evidence concerns the gene CD44 and breast cancer.